JPY 653.0
(-1.51%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | -388.4 Million JPY | -41.05% |
2022 | -275.36 Million JPY | 43.71% |
2021 | -489.15 Million JPY | 21.21% |
2020 | -620.8 Million JPY | -105.56% |
2019 | -302 Million JPY | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q1 | -412 Million JPY | -6.07% |
2023 Q4 | -388.4 Million JPY | -166.24% |
2023 Q3 | -145.88 Million JPY | 29.66% |
2023 Q2 | -207.4 Million JPY | 27.06% |
2023 Q1 | -284.34 Million JPY | -3.26% |
2023 FY | -388.4 Million JPY | -41.05% |
2022 Q3 | -120.48 Million JPY | 56.58% |
2022 Q2 | -277.52 Million JPY | 0.0% |
2022 Q4 | -275.36 Million JPY | -128.54% |
Name | Net Debt | Net Debt Difference |
---|---|---|
Shin Nippon Biomedical Laboratories, Ltd. | 16.05 Billion JPY | 102.419% |
Cosmo Bio Company,Limited | -2.8 Billion JPY | 86.158% |
H.U. Group Holdings, Inc. | 41.99 Billion JPY | 100.925% |
FALCO HOLDINGS Co., Ltd. | -9.24 Billion JPY | 95.8% |
BML, Inc. | -68.84 Billion JPY | 99.436% |
Human Metabolome Technologies, Inc. | -1.56 Billion JPY | 75.137% |
Precision System Science Co., Ltd. | -548.58 Million JPY | 29.199% |